Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors
Table 2
Characteristics of subjects who received radioactive iodine for differentiated thyroid cancer, stratified by nationality as Lebanese versus non-Lebanese.
Nationality
value
Lebanese N = 118
Non-Lebanese N = 56
Gender n (%)
Male
31 (26.3)
19 (33.9)
0.30
Female
87 (73.7)
37 (66.1)
Age, mean (±SD)
44.2 ± 15.2
39.8 ± 12.2
0.06
BMI, mean (±SD)
27.4 ± 5.2
30.9 ± 7.6
0.004
SBP, mean (±SD)
123.5 ± 15.3
128.6 ± 16.4
0.05
DBP, mean (±SD)
78.1 ± 11.5
82.2 ± 11.8
0.03
Tumor pathology n (%)
PTC
108 (91.5)
54 (96.4)
0.42
FTC
8 (6.8)
2 (3.6)
Other
2 (1.7)
0 (0.0)
Recurrence, yes n (%)
17 (14.4)
9 (16.1)
0.77
Lymph node, yes n (%)
54 (56.8)
35 (81.4)
0.005
RAI dose n (%)
50 mCi
30 (25.4)
10 (17.9)
0.38
100 mCi
74 (62.7)
36 (64.3)
150 mCi
14 (11.9)
10 (17.9)
Thyrogen, yes
4 (3.4)
3 (5.5)
0.68
Pretherapy TSH (mIU/L) mean (±SD)
85.0 ± 22.2
81.5 ± 25.9
0.39
Pretherapy TSH (mIU/L)–categorical
<50
9 (8.2)
9 (16.7)
0.25
50–75
18 (16.4)
9 (16.7)
>75
83 (75.5)
36 (66.7)
Smoking, yes n (%)
32 (27.4)
7 (12.5)
0.03
Alcohol, yes n (%)
21 (17.8)
2 (3.6)
0.01
Dental problems, yes n (%)
2 (2.1)
1 (2.3)
1.00
Days off LT4, mean (±SD)
20.6 ± 16.1
37.1 ± 20.8
0.02
Days after surgery, mean (±SD)
40.3 ± 28.1
47.5 ± 56.3
0.45
Days off total, mean (±SD)
37.2 ± 27.5
45.2 ± 50.7
0.19
WBS resultn (%)
Negative
12 (13.0)
7 (20.0)
0.31
Positive
71 (77.2)
27 (77.1)
Distant
9 (9.8)
1 (2.9)
Treatment received n (%)
NSAIDs
11 (9.3)
9 (16.1)
0.60
Steroids
3 (2.5)
2 (3.6)
Both
2 (1.7)
4 (8.9)
10 patients did not have TSH levels available; 47 patients did not have WBS results available.
